Linagliptin in the therapy of diabetes mellitus in 2012 - novelties and perspectives

Abstract

Linagliptin is the fourth representative of DPP-4 inhibitor group that has been recently introduced to the clinical practice in Czech Republic. The aim of this paper is to review clinical efficacy of linagliptin and its position in the current type 2 diabetes treatment algorithm.

Keywords

• Linagliptin
• diabetes mellitus
• DPP-4 inhibitors